PD-1/PD-L1 Axis in Lung Cancer

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Cancer immunotherapies, particularly PD-1/PD-L1 blockade, have significantly advanced non-small cell lung cancer (NSCLC) treatment.
• However, only a limited number of patients respond to current PD-1 or PD-L1 therapies.
• PD-L1 expression is the sole approved biomarker for patient selection, highlighting a need for more effective predictive tools.

Purpose of the Study:

• To review the clinical development and future directions of PD-(L)1 blockade in lung cancer.
• To discuss the limitations of current biomarkers and the potential of emerging biomarkers for patient selection.
• To explore combination therapy strategies to enhance immunotherapy efficacy in NSCLC.

Main Methods:

• Literature review of clinical trials and research studies on PD-(L)1 inhibitors in lung cancer.
• Analysis of current and emerging biomarkers for predicting immunotherapy response.
• Evaluation of combination treatment strategies, including chemotherapy and CTLA-4 blockade.

Main Results:

• PD-1/PD-L1 blockade has shown revolutionary impact in NSCLC, with emerging benefits in early-stage disease.
• Tumor mutational burden and other novel biomarkers are expected to improve patient selection beyond PD-L1 expression.
• Combination therapies with chemotherapy or CTLA-4 blockade may broaden the patient population benefiting from immunotherapy.

Conclusions:

• Improving patient selection through advanced biomarkers is crucial for maximizing the benefit of PD-(L)1 blockade in lung cancer.
• Combination strategies hold significant potential to increase response rates and overcome resistance to immunotherapy.
• Future research should focus on integrating novel biomarkers and combination approaches for more effective NSCLC treatment.